Ace Blend Funding: Raises $9.91 Million in Series A2 Led by 3one4 Capital
- Ace Blend raised $9.91 million in a Series A2 round led by 3one4 Capital, with existing investor Fireside Ventures participating.
- Fireside Ventures previously led its $3.3 million pre-Series A round and has increased its investment in the latest round.
- The funding will support R&D, clinical trials, supply-chain integration, testing and new nutrition formats.
Nutrition startup Ace Blend has raised $9.91 million in a Series A2 funding round led by 3one4 Capital, with existing investor Fireside Ventures increasing its investment in the company.
Fireside Ventures had previously led Ace Blend’s $3.3 million pre-Series A round. The company has not disclosed its valuation or the individual contributions of investors in the latest round.
The fresh capital will be used to strengthen research and development, conduct clinical trials, improve supply-chain and testing capabilities, and develop new nutrition products. Ace Blend also plans to commercialise new nutrition formats, with the first products expected to launch in the fourth quarter of FY27, between January and March 2027.
About Ace Blend
Founded by Shivam Hingorani, Ace Blend began selling its products in 2018 after more than a decade of research. Saif Mehkri joined as co-founder in 2022, bringing nearly three decades of experience in the nutrition industry.
The company develops nutritional supplements across categories including heart health, immunity, sleep, recovery and brain health. Ace Blend follows a vertically integrated model covering ingredient sourcing, formulation and manufacturing.
The company says its product development process starts with scientific research to determine factors such as nutrient form, dosage and delivery method. It also works with global ingredient suppliers including DSM and TCI and says it has secured exclusive rights in India to certain technologies from these partners.
Ace Blend said its formulations are recommended by more than 400 doctors. It also uses accredited laboratories in Europe for clinical validation and automated testing, according to the company. These activities are part of its research and quality-control process and should not be interpreted as establishing clinical efficacy for every product.
The company reported 300% growth in FY26 and said more than 46% of its customers return to make repeat purchases. Ace Blend has not specified the financial metric used to calculate the reported 300% growth.
Funding to Expand Research and New Nutrition Formats
Ace Blend plans to use the latest funding to conduct clinical trials through contract research organisations, with the aim of publishing findings in scientific journals. It will also invest in supply-chain integration and batch-level testing covering nutritional accuracy, pesticide residues and heavy metals.
The company plans to conduct stability studies to assess product quality over time and strengthen its control over sourcing, manufacturing and quality consistency as volumes increase.
Ace Blend is also developing new nutrition formats for everyday consumption and says it holds issued patents covering some of these inventions. The first products based on these formats are expected to launch in Q4 FY27.